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Introduction: The effectiveness of self-monitoring of blood glucose (SMBG) in 
noninsulin-treated patients with type 2 diabetes (T2DM) remains unclear. We aimed to review 
the trials investigating the effects of SMBG in this population.
Methods: Medline was searched until June 29, 2009. Randomized controlled trials (RCTs) 
of at least 12 weeks’ duration were included. Data on the following aspects were gathered: 
patient and study characteristics, effects on HbA1c, quality of life and treatment satisfaction, 
and methodological quality.
Results: The search revealed 9 original RCTs. These studies were very heterogeneous, and 
5 were classified as of high quality. The studies with the best methodology did not show an 
effect of SMBG on HbA1c, the studies with the worst methodological quality did. Two out of 
the 4 studies that assessed quality of life showed a significant change in favor of the control 
group, 1 study showed a significant change in favor of SMBG.
Discussion and conclusion: We found an inverse relation between study quality and efficacy 
of SMBG. At this moment, there is no basis for general use of SMBG in noninsulin-treated 
T2DM patients.
Keywords: blood glucose self-monitoring, diabetes mellitus, type 2, blood glucose, hemoglobin A, 
glycosylated
Introduction
Self-monitoring of blood glucose (SMBG) is an important tool in the management of 
diabetes mellitus. Patients with type 1 diabetes frequently measure their blood glucose 
to evaluate and, if necessary, to adjust insulin treatment and lifestyle, and to detect 
hypoglycemia. It is recommended that patients should measure their blood glucose at 
least 3 times daily.1 Although effectiveness of SMBG has been established for insulin-
treated patients with type 2 diabetes (T2DM), the optimal frequency and timing of 
SMBG have not yet been established.2,3 There is still much debate about the use and 
effectiveness of SMBG in noninsulin-treated T2DM.4 Many trials have investigated 
the effects of SMBG in this specific group and many (systematic) reviews have been 
written on this topic with conflicting conclusions.5
In insulin-treated patients SMBG can lead to (instant) insulin dose adjustments, 
thereby improving glycemic control and/or reducing episodes of hypoglycemia. This cas-
cade is not applicable for patients not using insulin, because an instantaneously modifiable 
factor is lacking. Still, there are theoretically advantages of SMBG in this population 
as well. For instance, data of SMBG could be used during periodical consultation 
with the diabetes health care provider to start or titrate blood glucose-lowering agents. Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 156
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Furthermore, based on the measured blood glucose, patients 
could adjust physical activity or food intake, or both.
Many aspects need to be considered when evaluating the 
effects of SMBG in noninsulin-treated patients. Firstly, how 
SMBG is used depends on the patient’s level of diabetes 
education. Without any knowledge of the patient about the 
values to strive for it will be merely self-measurement and 
health care providers are needed to interpret the results 
and give advice on how to adjust physical activity and 
diet. Whereas, when the patient is fully informed about the 
treatment goals and is educated about how to achieve these 
goals, SMBG could function as a tool for self-regulation. 
Secondly, the frequency of measurements varies; SMBG 
can be performed infrequently or each day at fixed times, 
pre- or postprandial, or both. Thirdly, the population of 
noninsulin treated T2DM patients is heterogenic and may 
use SMBG differently. For example, newly diagnosed 
patients, who just started a specific diet versus patients 
on a maximum dosage of oral blood glucose-lowering 
agents, when insulin therapy will have to be the next step. 
Or patients in good glycemic versus patients in persistent 
poor glycemic control. Fourthly, in some situations the 
primary goal of the patient and the health care provider 
could not be to improve glycemic control with SMBG, 
but to improve the patient knowledge of diabetes and the 
effects of different behavior on glucose levels and thereby 
influencing nonclinical factors such as well-being and treat-
ment satisfaction. Furthermore, performing SMBG includes 
the patient drawing blood from his or her finger tip regularly. 
This procedure can be painful or frightening and may also 
have its impact on well-being on its own.
We aimed to review trials investigating the effects of 
SMBG in noninsulin-treated patients with T2DM. We did 
not focus only on the effects on glycemic control, but also 
on the effects on health-related quality of life and treatment 
satisfaction as well as on the methodological quality of the 
trials.
Methods
inclusion criteria of studies
Randomized controlled trials (RCTs) of at least 12 weeks’ 
duration were included for this review. These studies 
should have included noninsulin-treated patients with 
T2DM, the intervention group should use SMBG, and the 
control group should use any other form of measurement of 
glycemic control or should continue to receive usual care. 
Trials should have included measurements of glycosylated 
hemoglobin (HbA1c).
Search strategy
Medline was searched until June 29, 2009 using PubMed 
with the following combination of free text words and 
MeSH-terms:
(((self-measur* OR self-monitor*) OR (“Blood 
Glucose Self-Monitoring”[Mesh])) AND ((“Diabetes 
Mellitus”[Mesh]) OR (diabete* OR diabeti* OR diabeto*)))) 
AND (((randomized controlled trial[Publication Type] 
OR (randomized[Title/Abstract] AND controlled[Title/
Abstract] AND  trial[Title/Abstract])))  OR  syste-
matic[sb].
Articles were selected for full text reading based on 
their title and abstract by two of the authors (NK and JH). 
The references of the systematic reviews were checked for 
additional studies as well.
Data selection
The selected RCTs were carefully read and data on the 
following topics were gathered systematically by two 
of the authors (NK and KJJH): patient characteristics, 
treatment modality, duration of intervention and con-
trol, type of intervention and control, and the number 
of patients in each treatment arm. Data on changes in 
HbA1c and quality of life and treatment satisfaction were 
extracted both within and between treatment groups. 
Methodological quality of the trials was assessed using 
the same method as Welschen et al used in their Cochrane 
review.4 Eleven items pertaining to internal validity were 
applied:
  1.  Was the method of randomization adequate?
  2.  Was the treatment allocation concealed?
  3.    Were the groups similar at baseline regarding the most 
important prognostic indicators?
  4.  Was the patient blinded to the intervention?
  5.  Was the care provider blinded to the intervention?
  6.  Was the outcome assessor blinded to the intervention?
  7.  Were co-interventions avoided or similar?
  8.  Was the compliance acceptable in all groups?
  9.    Was the withdrawal/drop-out rate described and 
acceptable?
10.    Was the timing of the outcome assessment in all groups 
similar?
11.    Did the analysis include an intention-to-treat analysis?
Each item had a rating scale of “yes”, “no” or “don’t 
know”. Studies fulfilling 6 or more of the 11 quality criteria 
were considered to be of “high quality”. All studies scoring 
less than 6 of the criteria were rated as “low quality”. Studies 
of low methodological quality were not excluded.Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 157
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Results
Studies
The initial search identified 427 publications, of which 
31 papers were selected for full text reading based on title and 
abstract. These 31 studies included 17 potential systematic 
reviews and 14 potential RCTs. From the RCT selection, 
1 trial was excluded because of the inclusion of patients 
using insulin.6 In 2 studies, the intervention as well as the 
control group used SMBG.7,8 For 1 study 2 references9,10 were 
found and for another study 3 references were found.11–13 
One additional RCT14 was selected from the reference list 
of a systematic review.15 Consequently, 9 original RCTs 
were selected and will be discussed.9–14,16–21 Both authors 
(NK and JH) obtained the same results for the literature 
search. Of the 17 potential systematic reviews, 14 references 
qualified.4,15,22–33 Four references, however, were all based on 
the Cochrane review of Welschen et al.4,24,27,28 Two references 
were based on the review of Coster et al.31,32
Patient characteristics and treatment 
modality (see Table 1)
The included trials were almost all performed in Western 
Europe or the United States. One study included patients 
from several Eastern Europe countries and from Malaysia 
and Iran.14 Except for the study of Farmer et al11–13 all studies 
included patients in poor glycemic control indicated by 
HbA1c values ranging from 8.1% to 12.0% (mean values). 
The study by O’Kane et al included only patients with new 
onset diabetes.21 The duration of diabetes in the other studies 
ranged from 2.8 to 12.7 years. The majority of the included 
patients was treated with oral blood glucose-lowering agents. 
Furthermore, most patients were obese, and did not use or 
infrequently used SMBG prior to the study.
Study characteristics (see Table 2)
All studies had a duration of 24 weeks or longer, with 
the longest study duration being 12 months. Studies dif-
fered substantially regarding requested number of blood 
glucose values, ranging from 6 to 42 times a week, with 
most studies collecting some postprandial values. Patients 
in most studies received target glucose values to strive for. 
These targets were different between studies, and more 
recent studies used lower target values. Glucose values 
were mostly part of collected information which was used 
to give advice on lifestyle responses. In 4 studies strict 
algorithms were used to adjust blood glucose-lowering 
therapy.14,16,17,21 From the published data from the remaining 
5 studies it is not clear whether and if so on what basis 
therapy was adjusted.9–13,18–20 A dietician participated in 
most studies or specific advices about diet were given 
(in 1 study education about counting carbohydrates was 
given). Patients in the less intensive SMBG group of the 
study by Farmer et al did not receive such advice.11–13 
In some studies much time and effort of a multidisciplinary 
team was invested to support the patient with SMBG, while 
in another study SMBG was given to the intervention group 
without support or education. In 2 studies, the control 
group performed urine testing of blood glucose.16,18 In other 
studies usual care was continued or HbA1c was measured 
periodically in the control group. In the studies by Allen, 
Davidson, Fontbonne, Guerci, and in the less intensive 
group in the study by Farmer, it appears that except per-
forming SMBG or not, no differences exist between the 
intervention and control group.11–13,16–19 In other studies, 
the SMBG group received also additional information or 
got personal advice about diet and exercise.
Methodological quality of studies 
(see Table 3)
Four studies were of low quality, 5 studies were of high 
quality. The studies published by Farmer, Davidson, and 
O’Kane are the studies with the best methodology. However, 
all these studies had problems with the compliance of patients 
performing SMBG.11–13,17,21 In the study by Davidson et al 
compliance was less than 50%.17 The study described by 
Farmer et al reached compliance rates of 67% and 52% in 
the less and more intensive intervention groups, respectively. 
In the study by O’Kane et al 34% of the patients performed 
less than 80% of the requested measurements.
effect on glycemic control (see Table 4)
Three studies found a significant beneficial effect on HbA1c 
of SMBG compared to the control group.9,10,19 In the study 
by Guerci et al HbA1c decreased from 9.0% to 8.1% after 
6 months. This decrease in HbA1c was ∼0.3% more compared 
to the decrease in found in the control group (P = 0.009). 
In the study by Schwedes et al HbA1c decreased from 8.5% 
to 7.5%, which was ∼0.5% (95% CI –0.77, −0.11) more 
compared to the control group. In the study by Barnett 
et al HbA1c decreased from 8.12% to 6.95%, which was 
0.24% (95% CI –0.45, −0.03) more compared to the control 
group.14 Muchmore et al found a nonsignificant benefit 
of SMBG of ∼0.7%.20 In the other studies nonsignificant 
differences between SMBG and control groups were 
between −0.2% and 0.1%.Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 158
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Table 2 randomized controlled trails of self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes not using insulin: 
study characteristics
Study Duration Treatment arm Number 
of patients
Intervention Control Intervention/
Control
Schwedes9,10 24 weeks SMBG 6 times a day (pre- and 1 hour postprandial 
values), 2 days a week 
(1 week day and Sunday)  
Documentation of eating habits  
Documentation of state of well-being  
Patients were explained that combined information 
allowed them to make diet and lifestyle changes in order 
to improve glycemic control counseling to increase 
self-perception, to promote self-reflection and to 
enhance self-regulation  
Therapy adjustment?
Nonstandardized counseling with a 
focus on diet and lifestyle  
Therapy adjustment?
113/110
Farmer11–13 12 months 1. Less intensive
SMBG 3 times a day (1 fasting and 2 pre- or postprandial 
values), 2 days a week  
Strive for preprandial glucose concentrations of  
4–6 mmol/l and postprandial 6–8 mmol/L  
A diary was used to record goals, activities,  
and blood glucose results  
 
No information about how to interpret glucose values 
was given  
Therapy adjustment?  
2. More intensive 
in addition to ‘1. less intensive’:   
Training and support in timing, interpretation and using 
results also to enhance motivation and maintain adher-
ence to diet, physical activity and drug regimens  
encouragement to experiment with SMBG to explore 
the effects of specific activity  
Therapy adjustment?
HbA1c every 3 months  
 
 
 
A diary was used to record self-care 
goals and strategies for achieving them 
Usual (standardized) care  
information about eating and physical activity   
 
Therapy adjustment?
150/151/152
Allen16 6 months SMBG before meals every other day, at least 36 times 
a month Strive for glucose concentrations 7.7 mmol/L 
fasting and 8.8 mmol/L before lunch and dinner  
Algorithm to adjust blood glucose-lowering treatment 
Instructed by dietician about diet, fiber intake, ideal 
bodyweight, activity level
Urine testing before meals every other 
day, at least 36 times a month Strive for 
negative urine checks 
Algorithm to adjust blood 
glucose-lowering treatment. instructed 
by dietician about diet, fiber intake, ideal 
body weight, activity level
27/27
Davidson17 6 months SMBG before and between 1–2 hours after meals during 6 days 
a week; 2 times breakfast, 2 times supper and 2 times dinner  
record meals  5 visits to dietician; education about meal 
size and components on rise of postprandial glucose values   
Strive for glucose concentrations 7.15 mmol/L  
Algorithm to adjust blood glucose-lowering treatment
visits to dietician; education about 
meal size and components on rise of 
postprandial glucose values 
Algorithm to adjust blood 
glucose-lowering treatment
43/45
Fontbonne18 6 months SMBG twice every other day; fasting and 2 hours after 
dinner and on Sundays after lunch  
Consulting physician was allowed to adjust therapy
1. Urine testing twice every other day; 
fasting and 2 hours after dinner and on 
Sundays after lunch  
Consulting physician was allowed to 
adjust therapy  
2. every 2 months HbA1c testing with 
physician’s comment about metabolic 
control to patient 
Consulting physician was allowed to 
adjust therapy
68/72/68
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Table 2 (Coutinued )
Study Duration Treatment arm Number 
of patients
Intervention Control Intervention/
Control
Guerci19 24 weeks SMBG at least 6 times a week on 3 different days 
including a weekend day. Dietary advice about ideal 
bodyweight.   walking was encouraged as a form of 
exercise  
Therapy adjustment?
HbA1c every 12 weeks  
Dietary advice about ideal body weight  
walking was encouraged as a form of 
exercise  
Therapy adjustment?
345/344
Muchmore20 44 weeks SMBG: first 4 weeks: 6 times daily (pre- and 2 hour 
postprandial values)  
Next 16 weeks: 2 times daily (pre- and 2 hour 
postprandial values). Last 24 weeks: individual choice  
Strive for a postprandial increase of 2.2–3.9 mmol/L 
with, if necessary, adjustment of carbohydrate quantity 
and quality or change in exercise timing or intensity  
education about carbohydrate counting  
 
received behavioral weight program (90 min a week 
during the first 8 weeks). In addition, there were 3 and  
4 sessions with a dietician and diabetes nurse, 
respectively 
 
Goal was to lose 0.5–1.0 kg a week  
Therapy adjustment?
 
 
 
 
 
 
 
received general information about 
nutrition  
received behavioral weight program 
(90 min a week during the first 
8 weeks). in addition there were 3 and  
4 sessions with a dietician and diabetes 
nurse, respectively  
Goal was to lose 0.5–1.0 kg a week 
Therapy adjustment?
12/11
O’Kane21 12 months SMBG 8 times a week; 4 fasting and 4 postprandial 
values  
received advice on interpretation and appropriate 
(lifestyle) responses to high or low readings  
educational program  
3-month visits with doctor, diabetes nurse, and dietician  
Algorithm to adjust blood glucose-lowering treatment
 
 
 
 
educational program  
every 3 months visits with doctor, 
diabetes nurse, and dietician  
Algorithm to adjust blood glucose-
lowering treatment
96/88
Barnett14 27 weeks SMBG 5 times a day (before each meal, 2 hours after 
the main meal and before bedtime), 2 days a week 
(1 working and 1 nonworking day). Once a month post-
prandial measurements after each meal  
Diet and lifestyle advice  
Diary was used to record symptoms of hypoglycemia 
and actions taken  
 
Algorithm to adjust blood glucose-lowering treatment
 
 
 
 
Diet and lifestyle advice  
Diary was used to record symptoms of 
hypoglycemia and actions taken  
Algorithm to adjust blood 
glucose-lowering treatment
311/299
effect on quality of life and treatment 
satisfaction (see Table 5)
In 4 studies, quality of life and treatment satisfaction were 
assessed using questionnaires. In the study of Muchmore et al no 
differences in quality of life were found between the intervention 
(SMBG) and control group (usual care).20 Although no 
significant difference was found for the total score on the patient 
well-being questionnaire in the study by Schwedes et al, 2 sub 
items (“depression” and “lack of well-being”) improved with 
SMBG compared to control.9,10 In contrast with these findings, 
2 more recent trials reported that SMBG was associated with 
lower quality of life.11–13,21 In the study by Farmer et al quality 
of life, as measured with the EQ-5D questionnaire, was lower in 
the more intensive intervention group compared to the control 
group.11–13 In the study by O’Kane et al the depression scale 
of the well-being questionnaire was significantly worse in the 
SMBG group compared to the control group.21 No differences 
were found concerning treatment satisfaction.
Discussion and conclusion
Nine RCTs investigating the efficacy of SMBG in 
noninsulin-treated patients with T2DM have been published Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 161
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Table 3 randomized controlled trails of self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes not using insulin: 
methodological quality
Criteria Schwedes9,10 Farmer11–13 Allen16 Davidson17 Fontbone18 Guerci19 Muchmore20 O’Kane21 Barnett14
randomization adequate + + + + + + + + +
Treatment allocation concealed + − − +
Groups similar at baseline + + + + + + + + +
Patient blinded NA NA NA NA NA NA NA NA NA
Care provider blinded NA NA NA NA NA NA NA NA NA
Outcome assessor blinded +/?a +/?a
Co-interventions avoided − + + + + + +
Compliance acceptable + − + − + + –
withdrawal/drop-out rate 
acceptable
+ + + + + − + + +
Timing of outcome assessment 
similar
+ + + + + + + + +
intention to treat analyses − + − + + +
Total quality score 5 (7)8 6 7 5 5 5 (6)7 6
Overall quality conclusion Low High High High Low Low Low High High
aOutcome assessor was only blinded for HbA1c.
Abbreviation: NA, not applicable.
so far.9–14,16–21 One third of the studies reported a positive 
effect of SMBG on HbA1c ranging from a 0.2% to 0.5% 
decrease. None of the studies published found a negative 
effect of SMBG on HbA1c. The evidence is more conflicting 
about the effects on quality of life. SMBG, as discussed in 
the introduction, is a complex intervention, although one 
can debate whether or not SMBG should be classified as an 
intervention in patients who “only” self-monitor without any 
form of self-regulation.
The differences in patient and study characteristics are 
distinct and complicate direct comparison between the 
studies. For example, mean HbA1c ranges from 7.5% to 12%. 
Furthermore, timing and frequency of SMBG vary widely, 
some studies advise patients which values to strive for, some 
studies give advice how to achieve these goals, and in some 
studies patients receive additional help from a dietician or 
a diabetes specialist nurse. These large differences in study 
design illustrate the many different ways that SMBG is 
integrated in the management of noninsulin-treated patients 
with T2DM and make it almost impossible to draw a single 
overall conclusion about its effectiveness.
Regardless of the heterogeneity of the studies, it is 
remarkable that there is an inverse relationship between 
study quality on the one hand, and efficacy on glycemic 
control and quality of life parameters on the other. Only 
1 study of high methodological quality found a significant 
Table 4 randomized controlled trails of SMBG in patients with type 2 diabetes not using insulin – study results: HbA1c
Study Treatment arm
Intervention Control Intervention vs Control
Schwedes9,11 8.47  7.47 8.35  7.81 –0.46 (95% Ci –0.77, –0.11)
Farmer11–13 1. 7.41  7.28  
2. 7.53  7.36
7.49  7.49 1. – 0.14 (95% Ci –0.35, 0.07)   
2. –0.17 (95% Ci –0.37, 0.03)
Allen16 12.4  10.4 11.7  9.7 ∼0.0 (P  0.95)
Davidson17 8.5  7.7 8.4  7.8 –0.2 (95% Ci –1.1, 0.6)
Fontbonne18 8.2  ∼7.8 1. 8.6  ∼8.5  
2. 8.2  ∼7.7
1. ∼ –0.2 (NS)  
2. ∼0.1 (NS)
Guerci19 9.0  8.1 8.9  8.4 ∼ –0.3 (P = 0.009)
Muchmore20 10.29  8.75 10.45  9.6 ∼ –0.7 (NS)
O’Kane21 8.8  6.9 8.6  6.9 –0.07 (95% Ci –0.38, 0.25)
Barnett14 8.12  6.95 8.12  7.20 –0.24 (95% Ci –0.45, –0.03)Diabetes, Metabolic Syndrome and Obesity:   Targets and Therapy 2009:2 162
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improvement of HbA1c of 0.24% (95% CI 0.03, 0.45) with 
SMBG compared to control.14 The other 4 well designed 
studies found no effects of SMBG on glycemic control, but 
did report a worsening of quality of life parameters compared 
to control.11–13,16,17,21 When comparing the study by Barnett 
et al with the other well designed studies in order to find a 
possible explanation for the differences in effects on HbA1c, 
no major differences were found for the interventions used. 
What was somewhat different in the study by Barnett et al is 
the shorter diabetes duration and the lower body mass index 
(BMI) of patients included (Table 1).
Two recent systematic reviews concluded that the effect 
of SMBG on HbA1c was on average 0.21% and 0.22%.15,22 
One may question, however, whether it is justified to perform 
a meta-analysis including all the trials, keeping in mind that 
the benefits of SMBG were found primarily in low quality 
trials. A Cochrane review did not perform a meta-analysis 
because of the differences in study quality and because of 
the differences in baseline data of the patients and type of 
interventions between the studies.4,34
A collaboration of authors of previous trials will inves-
tigate whether a certain subgroup of patients can be found 
who might benefit more from SMBG than the effects found 
in the systematic reviews.5 Perhaps, a short diabetes duration 
and a low BMI could be factors as hypothesized earlier. On 
top of that, a large RCT will be performed in the Netherlands 
including 600 patients with noninsulin-treated T2DM, 
in which the patients will be randomized into 3 groups: 
SMBG, self-measurement of urine glucose, and control.35 
Perhaps, these 2 studies will give some new perspectives 
about the usefulness of SMBG in certain subgroups of 
patients. Until then, we recommend that SMBG should 
not be used generally in a population of noninsulin-treated 
diabetic patients. Effectiveness on glycemic control has not 
been established, and quality of life could diminish.
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